<DOC>
	<DOCNO>NCT02066896</DOCNO>
	<brief_summary>This study design test efficacy safety low laser therapy treat xerostomia patient primary Sjogren 's Syndrome .</brief_summary>
	<brief_title>Laser Therapy Treat Dry Mouth Sjogren 's Syndrome</brief_title>
	<detailed_description>The Sjogren 's Syndrome disease affect around 0,5 % population mainly characterize inflammatory involvement salivary lacrimal gland . The xerostomia lead low quality life cause dry sensation disturb taste , speaking , swallow chew function affect patient . The absent saliva cause increase dental caries decay . Until , effective treatment increase amount saliva patient low improvement cholinergic drug pilocarpine cevimeline . These drug cause unpleasant collateral effect .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Patients primary Sjogren Syndrome accord criterion american european 2002 . Salivary flux non stimulate &lt; 0,1 ml/min . hepatitis B and/or C radiotherapy glandular area ( previous ) connective disease thyroidopathy non compensate GVHD graftversushost disease HIV Sarcoidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Sjogrens Syndrome</keyword>
	<keyword>Syndrome , Sjogren 's</keyword>
	<keyword>Sjogren Syndrome</keyword>
	<keyword>Sicca Syndrome</keyword>
	<keyword>Syndrome , Sicca</keyword>
</DOC>